Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
GEu1jwcNzESvdNaP
